Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Water Smart Connect (Water Smart Connect)

Framework: Horizon Europe — Innovative Europe
Programme: European innovation ecosystems
Theme: Interconnected Innovation Ecosystems
Destination: Interconnected Innovation Ecosystems
Action type: Coordination and support actions
Countries involved: Finland,Denmark,Netherlands,Spain,France
Call: Preparatory action for setting up joint programmes among innovation ecosystems actors (HORIZON-EIE-2023-CONNECT-01, 2023)
Start date: 2024-06-01
End date: 2025-06-30
Duration (months): 13.0
Total project cost (EUR): 499091.32
EU funding (EUR): 499091.32
Participants: 11
Project status: SIGNED

Today’s urgent challenges are inherently complex and systemic and will not be solved by individual actors or territories in isolation. To foster enabling innovation ecosystems across the EU, a systemic approach that is inclusive and collaborative is required. Diverse actors from separate regions ensure an equitable diffusion of benefits and maximise the value of innovation for all. This project aligns with EIE’s aims to create more connected, inclusive and efficient innovation ecosystems that support the scaling of companies and spur innovation to address important challenges in a responsible way. Previous projects and collaboration (i.e. WST, S3P) are used as the foundation for this further development. Proposal topics The project will focus on digitalisation within water-heavy sectors as an enabler to create a water smart society. Concept The project will take a threefold approach to driving cross-regional innovation with the water-smart focus area. These are: 1) Prioritisation of key innovation areas Regionally, the project will generate a base of qualitative and quantitative data on existing capacities, gained from partners' experience and knowledge, and through engagement of quadruple-helix stakeholders. This process will drive the identification of innovation priority areas regionally. 2) Cross-regional actions Through cross-regional workshops, key innovation areas and gaps will be identified with a focus on formulating cross-regional action plans that generate a pipeline of specific ideas / concepts for future projects. The workshops will analyse gaps in the competences of each of the regions to foster cross-regional collaboration. 3) Idea generation and partner matching Based on the cross-regional workshops, the partners will select / match key innovation ideas and stakeholders through workshops, webinars, and digital co-creation. The focus will be to develop a pipeline of concepts for future collaboration ( E.g. EUREKA, Water4All, Horizon Europe)

Keywords: water technology,water smart society,cross regional collaboration,ecosystem development
CONSOLIDATING THE EXPERTISE OF NECMETTIN ERBAKAN UNIVERSITY TOWARDS THE DEVELOPMENT OF BIOFIBERS FOR WOUND HEALING AND TISSUE REGENERATION (REGENEU)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Türkiye,Ireland,Germany
Call: Twinning (HORIZON-WIDERA-2021-ACCESS-03, 2021)
Start date: 2022-10-01
End date: 2025-09-30
Duration (months): 36.0
Total project cost (EUR): 1446071.25
EU funding (EUR): 1446071.25
Participants: 5
Project status: SIGNED

Biomaterials have gained much interest as a very important category of materials because of their wide application in medicine and benefit to patient such as increased longevity and improved quality of life. There is clear evidence of a stable increase of the biomaterials market for the next fifteen years. European Biomaterials Market represents a market of 7 € billion and the global Biomaterials market is five times the European market. Biomaterials sector has not yet been in a good position among the high-value chains in Turkey. Turkey imports biomedical devices, instruments and materials, especially Advanced Therapy and Medicinal Products (ATMPs) about 85%. In Turkey, few R&D activities and limited coordination of academy-industry are the main barriers to develop competitive biomaterial products and high value research in biomaterials field in Turkey. Necmettin Erbakan University (NEU) is a young University in Konya-Turkey with well-equipped Faculty of Medicine, Faculty of Dentistry, Institute of Science and the dedicated research center, Science and Technology Research and Application Centre, brings together the scientists researching on medicine, material, energy, biomaterial sciences and focusing on creative answers to today's scientific challenges. NEU has weakness on developing functional biofibers for medicinal applications, specifically to be applied in wound healing and tissue regeneration. The proposal REGENEU aims to meet the requirements of the HORIZON-WIDERA-2021-ACCESS-03-01: Twinning Call. The main focus of this project is to increase the scientific capabilities and excellence of NEU in the field of biofiber research and development for translational application. This target is supported by European partners Fraunhofer (Germany), UKW (Germany), TCD (Ireland) and RCSI (Ireland). NEU needs to transfer knowledge about its weak side, on the development and production of innovative and GMP conform functionalized biofibers for wound healing.

Keywords: biomaterial,biofiber,wound healing,tissue regeneration
Moving Forward: Implementing the EU Space Strategy for Security & Defence (2028 – 2034) (EUSTAR)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Italy
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-11-03
End date: 2027-11-02
Duration (months): 24.0
Total project cost (EUR): 193643.28
EU funding (EUR): 193643.28
Participants: 1
Project status: SIGNED

The EUSTAR project critically examines the implementation of the EU Space Strategy for Security and Defence, identifying significant gaps in current policy frameworks, particularly regarding regional contributions and stakeholder integration across Europe. Despite the EU’s recognition of space as a vital domain intersecting multiple policy areas, the strategy has not been thoroughly analyzed from an interdisciplinary social sciences perspective. EUSTAR addresses this gap by focusing on three key areas: the need for a comprehensive assessment of the EU Space Strategy for Security and Defence and its objectives in anticipation of the Multiannual Financial Framework (2028-2034); the overlooked role of Regions as pivotal subnational actors in European space policy; and the limited scholarly attention paid to European space policy. Utilizing an interdisciplinary methodology that incorporates qualitative and quantitative research, scenario planning, foresight methodologies, and extensive stakeholder consultations, EUSTAR develops nuanced policy recommendations aimed at optimizing strategic alignment, enhancing regional engagement, and fostering cross-sectoral innovation. The project also emphasises inclusivity by integrating gender and diversity considerations into its analysis, thereby addressing systemic inequalities within the space sector. The expected outcomes include the advancement of theoretical frameworks for understanding European space policy, practical recommendations for resource allocation within the Multiannual Financial Framework (2028-2034), and the creation of an open-access toolkit for stakeholders. By bridging academic and policy-oriented approaches, EUSTAR will contribute to a more integrated and effective implementation of the EU Space Strategy for Security and Defence, enhancing the EU's strategic autonomy, economic growth, and resilience in the critical domain of space.

Keywords: space policy,aerospace,safety and security,regions,space technology
Non-Native Language Processing and Production: Evidence for an Integrated Grammar (NNLPP)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Norway
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-01-01
End date: 2025-06-30
Duration (months): 30.0
Total project cost (EUR): 226751.04
EU funding (EUR): 226751.04
Participants: 1
Project status: CLOSED

The project responds to a vital need in the modern European society to put scientific research behind language-related policies and decisions that define the statuses of different languages in the European community. It makes a scientific step towards a better understanding of multilingualism and language acquisition. NNLPP is an integrated study of processing and production which compares the strategies multilingual speakers use across their languages. The project will investigate adult non-balanced multilinguals of 250-300 participants speaking languages that belong to different linguistic families: Norwegian, Russian, Armenian and English. I will carry out a series of studies that will measure processing time and eye movements, and will record speech patterns. NNLPP will provide a well-rounded description of psycholinguistic mechanisms of language processing and production used by a multilingual mind in sentences with code-switching.

Keywords: non native language processing and production by non balanced multilinguals
Artificial Intelligence and Machine Learning for Enhanced Representation of Processes and Extremes in Earth System Models (AI4PEX)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Climate
Destination: Climate sciences and responses for the transformation towards climate neutrality
Action type: Research and Innovation actions
Countries involved: Germany,France,Finland,Denmark,Sweden,Spain,Belgium,Switzerland,United Kingdom,Czechia
Call: Further climate knowledge through advanced science and technologies for analysing Earth observation and Earth system model data (HORIZON-CL5-2023-D1-01, 2023)
Start date: 2024-04-01
End date: 2028-03-31
Duration (months): 48.0
Total project cost (EUR): 7135788.75
EU funding (EUR): 7135788.75
Participants: 20
Project status: SIGNED

Global warming continues at an alarming rate, presenting unprecedented challenges to society that require urgent, science-led mitigation and adaptation. Earth system models (ESMs) are essential tools for projecting climate change, providing important information to decision makers. However, confidence in predicted climate change is undermined by a number of uncertainties; (i) ESMs disagree on how much the Earth will warm for a given increase in atmospheric carbon dioxide (CO2) (Earth’s equilibrium climate sensitivity); (ii) how much emitted CO2 will stay in the atmosphere to warm the planet (half the CO2 emitted by humans has been absorbed by the land and ocean) and (iii) how much excess heat in the Earth system will enter the ocean interior, delaying surface warming (~90 % of the heat in the Earth system goes into the ocean). Central to these uncertainties are poorly understood, and poorly modelled, Earth system feedbacks, in particular cloud feedbacks, carbon cycle feedbacks and ocean heat uptake. Poor representation of these phenomena degrades the accuracy of ESM projections, with implications for anticipating future climate extremes and societal impacts. We aim to improve the representation of these feedbacks in ESMs, reducing uncertainty in global warming projections. We propose a multidisciplinary approach, focused on “learning” how to accurately describe processes underpinning these feedbacks, through a fusion of observations with advanced machine learning (ML) and artificial intelligence (AI). Such data and approaches, constrained by the laws of physics, will deliver a step change in the accuracy of Earth system models. AI4PEX will place Europe at the forefront of a revolution in Earth system modelling, leading to increased accuracy of climate change projections and superior support for implementation of the Paris Climate Agreement and the European Green Deal.

Keywords: climate big data,climate explainability,climate ecosystems interactions,extreme events,earth system modelling,explainable artificial intelligence,climate data science,model data fusion,earth observation
Chronic PAIN eradiCAtion by taRgeting Schwann cElls (PAIN-CARE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Italy
Call: ERC PROOF OF CONCEPT GRANTS2 (ERC-2022-POC2, 2022)
Start date: 2023-11-01
End date: 2025-04-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 2
Project status: CLOSED

About 25% of the adult population experiences chronic pain, which disrupts daily activities and severely affects the patient’s quality of life. In Europe, the socioeconomic burden of chronic pain runs into billions of euros annually and represents 3–10% of the GDP. The current mainstays of pain treatment are non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, but their prolonged use is frequently associated with life-threatening adverse events and physical dependence. There is therefore an urgent need for new pharmacological strategies with superior efficacy and safety than those of NSAIDs and opioids. PAIN-CARE proposes to address chronic pain signaling using inhibitors targeting the Schwann cell proalgesic pathway. Previous research has shown the crucial role of Schwann cells in sustaining chronic pain. This project aims at developing Schwann cell selective drugs for chronic pain treatment, creating more clinically ready compounds based on bifunctional chimeric antagonists, with an inhibitory activity 100% higher than that of the combination of the two individual antagonists in mouse chronic pain models. The new Schwann Cell selective Analgesic Drugs (SCADs) will provide a dramatic change in the pain treatment paradigm, reducing treatment-related side effects and improving persistence. During this PoC, we aim to identify lead bifunctional chimeric molecules that preferentially antagonise two Schwann cell proteins. We will carry out tests in vitro and in vivo to demonstrate the novel compounds’ feasibility and superior inhibition efficiency when compared to the currently used compounds. Furthermore, our aim is to translate the results to a pre-commercialisation phase through the definition of the innovation commercial feasibility and potential, which will then be validated in discussions with relevant market players. A strong IPR strategy will be designed to ensure an advantageous position in the value chain of analgesics for pain treatment.
A versatile biosensor of strigolactone responses in plants (StrigoSense)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Italy
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-12-01
End date: 2026-11-30
Duration (months): 24.0
Total project cost (EUR): 172750.08
EU funding (EUR): 172750.08
Participants: 1
Project status: SIGNED

Strigolactones (SLs) are a class of plant hormones that participate in many plant environmental interactions, including responses to drought. Much still has to be understood about how they mediate plant responses to abiotic stresses, but their mapping and quantification in plant tissues is extremely difficult. Some SL biosensors have been developed in recent years, but they all suffer from some technical limitations: namely they are negative sensors whose signal is degraded in the presence of SLs, and they require laborious and invasive techniques for signal detection. The aim of this fellowship is thus to combine knowledge in the fields of plant synthetic biology and plant molecular physiology to construct a novel SL biosensor, called StrigoSense, which is positively activated in the presence of SLs. StrigoSense will be constructed using the principles of modularity and reusability: this will allow to pair it with many customisable reporter systems, creating a tool which can accomodate a variety of users and research applications. In this project, StrigoSense is coupled to fluorescent and bioluminescent reporters for the non-invasive monitoring of plant SL responses at the cell and system level. The biosensor will be developed in Arabidopsis and tomato plants, seeking to transfer the research conducted on model organisms to a crop of enormous relevance, narrowing the gap between basic research and the development of SL-based agricultural solutions. After fine-tuning, the biosensor will be used to monitor plant responses to different abiotic stresses and to an array of SL-like compounds and biostimulants with the potential of acting as priming agents that help plants cope with recurring water deficits. This will be the first example of the testing of a SL biosensor under physiological stress conditions. The technical advantages of StrigoSense will make SL biosensors faster, cheaper and more high-throughput, with benefits for basic and applied research.

Keywords: strigolactones,biosensors,crispra,stress responses,crop adaptation,priming agents
An integrative genetic approach for the exploration of melanoma immunological interactions (Mel-Immune)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: Israel
Call: ERC ADVANCED GRANTS (ERC-2022-ADG, 2022)
Start date: 2023-10-01
End date: 2028-09-30
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Immunotherapy, which has revolutionized cancer treatment, largely relies on the immune system’s recognition of neopeptides, degradation products of altered proteins specific to cancer cells presented on their surface. In particular, cancer vaccines targeting neopeptides have shown promising clinical results. Yet, to optimize their efficacy and broaden their application, we need to decipher the nature of the cancer peptide landscape (immunopeptidome) and delineate the neopeptide properties required to induce a potent immune response. The overarching goal of this proposal is to provide an unprecedented, thorough, multifaceted understanding of the mechanisms underlying aberrant peptide production, peptide-MHC presentation, and T-cell recognition in melanoma. We will do so by pursuing three key avenues: Systematic interrogation of the cancer immunopeptidome to identify novel canonical and non-canonical cancer antigens and quantify their presentation (Aim 1). Comprehensive functional assessment of the intrinsic qualities of actionable antigens by quantitatively charting the immunopeptidome in-vivo, while considering peptide presentation levels, clonality and cross-presentation; and delineating how these neoantigen qualities impact the immune response (Aim 2). Establish controlled in-vivo models to tease apart neoantigen qualities for the establishment of rational cancer vaccine modalities (Aim 3). In this effort, we will draw upon our pioneering tools and advanced mapping of the cancer peptidome in melanoma, which has already revealed novel antigenic sources. Our research approach combines comprehensive quantitative immunopeptidomics, novel imaging and computational approaches, advanced functional assays and novel mouse models. Our project will provide a fresh view of melanoma-immune interactions, new research tools and pipelines, cancer-specific antigen targets for immunotherapy and, more broadly, a paradigm for addressing similarly complex questions in other cancers.

Keywords: melanoma,cancer genetics,somatic mutation,neopeptide,neoantigen,cancer vaccine,immunotherapy,immunopeptidome,mhc class i
Smart Microrobotic Biopsy: A Leap Forward in Brain Disease Diagnostics (SmartMicroBiopsy)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2025-07-01
End date: 2027-06-30
Duration (months): 24.0
Total project cost (EUR): 3567043.76
EU funding (EUR): 2496930.63
Participants: 1
Project status: SIGNED

Over 1B people worldwide suffer from brain diseases, including neurodegenerative disorders, cancers, and functional conditions like epilepsy and depression, incurring an annual treatment cost of €1.7T. Specifically in Europe, the cost reached €800B in 2010, increasing each year. Annually, 350k people are diagnosed with primary brain tumours, resulting in 250k deaths. Additionally, brain metastases affect over 1M individuals yearly. Addressing this socio-economic challenge requires precise medical interventions. Current tools in neurosurgery, such as catheters, needles, and electrodes, are limited to straight paths dictated by the initial skull opening, restricting access to critical tumour sites and thus limiting treatment options. Robeaute's microrobotics is transforming robotic surgery by enhancing surgical precision and introducing micro and nano techniques for targeting cells directly, facilitating improved diagnostics and treatments. These microrobots perform intricate 3D movements, allowing unprecedented access to critical areas affected by brain diseases. Unlike traditional passive microrobots, which rely on large coils and cannot perform biopsies, Robeaute is pioneering an active, self-propelled microrobot designed for in vivo intracerebral 3D navigation, leading to 54 patent filings. WIth EIC support, Robeaute aims to conduct First in Human and pivotal clinical trials targeting the brain biopsy market, focusing initially on challenging areas such as paediatric brainstem tumours, recurrent tumours requiring multiple biopsies, primary tumours for comprehensive profiling, and metastases unresponsive to traditional treatments. These specific niches represent a potential market of €0.3B in the US and Europe. The broader biopsy market, valued at €3.67B, is expanding with the rise of personalised therapies for brain tumours, necessitating increased biopsy procedures to aid in treatment selection and the development of personalised treatments like cancer vaccines.

Keywords: brain biopsy,drug delivery,microrobot,neurosurgery,3d navigation,microengineering